Nuvalent, Inc. NUVL
We take great care to ensure that the data presented and summarized in this overview for Nuvalent, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NUVL
View all-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.74 Billion28.96% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$509 Million14.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$444 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$292 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA2.3MShares$222 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X02.19MShares$211 Million0.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.81MShares$175 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY1.67MShares$162 Million0.01% of portfolio
-
State Street Corp Boston, MA1.57MShares$152 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY1.56MShares$151 Million0.3% of portfolio
Latest Institutional Activity in NUVL
Top Purchases
Top Sells
About NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at NUVL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2026
|
James Richard Porter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+12.46%
|
-
|
|
Jan 07
2026
|
Alexandra Balcom Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+14.99%
|
-
|
|
Jan 07
2026
|
Christopher Durant Turner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+19.42%
|
-
|
|
Jan 07
2026
|
Deborah Ann Miller Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+22.69%
|
-
|
|
Jan 07
2026
|
Darlene Noci Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+23.14%
|
-
|
|
Jan 07
2026
|
Henry E. Pelish Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+17.35%
|
-
|
|
Jan 06
2026
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
9,543
-1.11%
|
$925,671
$97.49 P/Share
|
|
Jan 06
2026
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,181
-1.26%
|
$308,557
$97.49 P/Share
|
|
Jan 06
2026
|
Christopher Durant Turner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,181
-1.85%
|
$308,557
$97.49 P/Share
|
|
Jan 06
2026
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,589
-1.96%
|
$251,133
$97.49 P/Share
|
|
Jan 06
2026
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,181
-2.47%
|
$308,557
$97.49 P/Share
|
|
Jan 06
2026
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,664
-1.31%
|
$258,408
$97.49 P/Share
|
|
Jan 05
2026
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
17,890
-1.49%
|
$1,735,330
$97.35 P/Share
|
|
Jan 05
2026
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,236
-1.21%
|
$410,892
$97.35 P/Share
|
|
Jan 05
2026
|
Christopher Durant Turner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,236
-1.73%
|
$410,892
$97.35 P/Share
|
|
Jan 05
2026
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,363
-2.29%
|
$423,211
$97.35 P/Share
|
|
Jan 05
2026
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,236
-2.27%
|
$410,892
$97.35 P/Share
|
|
Jan 05
2026
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,496
-0.89%
|
$242,112
$97.35 P/Share
|
|
Jan 02
2026
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-5.92%
|
$1,000,000
$100.76 P/Share
|
|
Jan 02
2026
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.47%
|
$180,000
$18.93 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 164K shares |
|---|---|
| Exercise of conversion of derivative security | 738K shares |
| Open market or private sale | 1.52M shares |
|---|